AT7519

别名: AT7519M

AT7519 是多种CDK抑制剂,作用于CDK1, 2, 4, 6和9时,IC50为10-210 nM,对CDK3作用效果稍弱,对CDK7几乎没有抑制活性。AT7519 也可抑制GSK3β的磷酸化。AT7519 可诱导凋亡。Phase 2。

AT7519 Chemical Structure

AT7519 Chemical Structure

CAS: 844442-38-2

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1405.32 现货
5mg RMB 903.68 现货
25mg RMB 3016.98 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

客户使用Selleck的AT7519发表文献49

产品质控

批次: S152402 DMSO] 25 mg/mL] false] Water] Insoluble] false] Ethanol] Insoluble] false 纯度: 99.9%
99.9

AT7519相关产品

相关信号通路图

CDK抑制剂选择性比较

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
A2780 Antiproliferative assay 72 hrs Antiproliferative activity against human A2780 cells assessed as cell viability after 72 hrs by alamar blue assay, IC50=0.35μM 18656911
HCT116 Antiproliferative assay 72 hrs Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by alamar blue assay, IC50=0.082μM 18656911
MRC5 Antiproliferative assay 72 hrs Antiproliferative activity against human MRC5 cells assessed as cell viability after 72 hrs by alamar blue assay, IC50=0.98μM 18656911
HCT116 Cytotoxicity assay 72 hrs Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by Alamar blue assay, IC50=0.08μM 26115571
MIAPaCa2 Antiproliferative assay 72 hrs Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay, IC50=0.411μM 30343954
AsPC1 Antiproliferative assay 72 hrs Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay, IC50=0.533μM 30343954
SUIT2 Antiproliferative assay 72 hrs Antiproliferative activity against human SUIT2 cells after 72 hrs by prestoblue assay, IC50=0.557μM 30343954
BxPC3 Antiproliferative assay 72 hrs Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay, IC50=0.64μM 30343954
S2-013 Antiproliferative assay 72 hrs Antiproliferative activity against human S2-013 cells after 72 hrs by prestoblue assay, IC50=2.77μM 30343954
Sf21 Function assay 2 hrs Inhibition of recombinant full-length human C-terminal His6-tagged CDK1/human full-length N-terminal GST-tagged Cyclin B expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate measured after 2 hrs in presence of gamma[32P] ATP b, IC50=0.21μM 30543440
HCT116 Antiproliferative assay 72 hrs Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by cell titer glo-based luminescence assay, IC50=0.132μM 31175010
HCT116 Function assay Inhibition of CDK1 in human HCT116 cells assessed as PP1-alpha(Thr320) phosphorylation 18656911
HCT116 Function assay Inhibition of CDK2 in human HCT116 cells assessed as Rb(Thr321) phosphorylation 18656911
HCT116 Function assay Inhibition of CDK2 in human HCT116 cells assessed as NPM(Thr199) phosphorylation 18656911
Sf21 Function assay Inhibition of recombinant human full length N-terminal His6-tagged CDK5/N-terminal GST-tagged p25 expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate, Ki=0.018μM 27171036
Sf21 Function assay Inhibition of human full length C-terminal His6-tagged CDK2/N-terminal GST-tagged cyclin A expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate, Ki=0.044μM 27171036
sf cells Function assay Inhibition of recombinant human N-terminal GST-tagged CDK4/cyclin D1 expressed in baculovirus infected sf cells, Ki=0.067μM 27171036
Sf21 Function assay Inhibition of recombinant human full length C-terminal His6-tagged CDK9/cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate, Ki<0.1μM 27171036
Sf21 Function assay Inhibition of human full length C-terminal His6-tagged CDK1/N-terminal GST-tagged cyclin B expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate, Ki=0.19μM 27171036
Sf21 Function assay Inhibition of recombinant human full length C-terminal His6-tagged CDK2/N-terminal GST-tagged cyclin E expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate, Ki=0.51μM 27171036
Sf21 Function assay Inhibition of recombinant human full length C-terminal His6-tagged CDK7/cyclin H/N-terminal GST-tagged MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 substrate peptide, Ki=2.8μM 27171036
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
HEI-OC1 Function assay Protection against cisplatin-induced cell death in neonatal mouse HEI-OC1 cells assessed as reduction in caspase-3/7 activity, EC50=0.38μM 30091915
Sf21 Function assay Inhibition of recombinant human full-length C-terminal His6-tagged CDK9/human full-length untagged cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate, IC50<0.01μM 30543440
Sf21 Function assay Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate, IC50=0.36μM 30543440
Sf21 Function assay Inhibition of recombinant human C-terminal His6-tagged full length CDK7/untagged recombinant full length human Cyclin H/N-terminal GST-tagged recombinant full length human MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 peptide as subs, IC50=2.4μM 30543440
点击查看更多细胞系数据

生物活性

产品描述 AT7519 是多种CDK抑制剂,作用于CDK1, 2, 4, 6和9时,IC50为10-210 nM,对CDK3作用效果稍弱,对CDK7几乎没有抑制活性。AT7519 也可抑制GSK3β的磷酸化。AT7519 可诱导凋亡。Phase 2。
靶点
CDK9/CyclinT [1]
(Cell-free assay)
CDK5/p35 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
GSK-3β [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
点击更多
<10 nM 13 nM 47 nM 89 nM 100 nM
体外研究(In Vitro)
体外研究活性 AT7519是ATP竞争性CDK 抑制剂,作用于CDK1 时Ki值为38 nM。 AT7519作用于所有非CDK激酶(除了GSK3β,IC50=89 nM)没有抑制活性。AT7519作用于多种人类肿瘤细胞系,显示有效的抗增殖活性,IC50值从作用于MCF-7的40 nM到作用于 SW620 的940 nM ,与抑制CDK1和 CDK2一致。[1] AT7519作用于多发性骨髓瘤(MM)细胞系48小时,诱导剂量依赖性毒性IC50值从 0.5到2 μM,最敏感细胞系为MM.1S (0.5 μM)和U266 (0.5 μM) ,最抵抗细胞为MM.1R (>2 μM), 但是作用于外周血单个核细胞(PBMNC)不会诱导毒性。AT7519部分克服由 IL6 和IGF-1引起的增殖优势,且保护骨髓基质细胞 (BMSCs)。AT7519 诱导RNA pol II CTD 在serine 2 和serine 5 位点快速去磷酸化, 且作用于MM 细胞通过产生毒性而抑制部分转录 。AT7519通过下调GSK-3β磷酸化而诱导 GSK-3β激活,也因为 AT7519诱导凋亡,但是不抑制转录。[2]
激酶实验 体外激酶实验
辐射滤波器结合格板上进行CDK1,CDK2和GSK3-β激酶实验。在DELFIA格式板上测定CDK5,在ELISA格式板上测定CDKs 4和 6。为了测定CDKs 1和2,相关的CDK 和0.12 μg/mL组蛋白H1在20 mM MOPS, pH 7.2, 25 mM β-甘油磷酸盐, 5 mM EDTA, 15 mM MgCl2, 1 mM原钒酸钠, 1 mM DTT, 0.1 mg/mL BSA, 45 μM ATP (0.78 Ci/mmol)和不同浓度AT7519的混合物中分别温育2或4小时。测定 GSK3-β,相关的酶和 5 μM糖原合酶肽2在10 mM MOPS pH 7.0, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% 甘油, 0.2 mM EDTA, 10 mM MgCl2, 0.01% β-巯基乙醇, 15 μM ATP (2.31 Ci/mmol) 和不同浓度AT7519 的混合物温育3小时。加入过量正磷酸终止反应,使用Millipore MAPH滤板过滤。然后冲洗板,加入闪烁剂,在 Packard TopCount上通过测定闪烁数而测量放射性。为了测定CDK5, CDK5/p35 和 1μM 生物素化的组蛋白H1肽段(生物素-PKTPKKAKKL) 在25 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 0.025% Brij-35, 0.1 mg/mL BSA, 1 mM DTT, 15 μM ATP 和不同浓度AT7519的混合物温育30分钟。使用EDTA终止反应,转移到 Neutravidin包被的板上,通过兔磷酸-cdk1 底物单抗和DELFIA Eu-标记的二抗抗兔 IgG,使用时间分辨荧光测定λex=335nm,λem=620nm处荧光值,而量化磷酸化底物。为了测定CDK 4和6,用 GST- pRb769-921包被板,然后用Superblock阻断。CDK4或6在15 mM MgCl2, 50 mM HEPES, pH 7.4, 1 mM DTT, 1 mM EGTA, pH 8.0, 0.02% Triton X-100, 2.5% DMSO 和不同浓度AT7519混合物中温育,加入 ATP开始反应。30分钟后,加入 0.5 M EDTA pH 8.0终止反应。冲洗板,和一抗温育1小时,然后在 Superblock上稀释,随后用碱性磷酸酶链接抗兔二抗再处理1小时。使用Attophos系统进行板显影,然后在Spectramax Gemini计数板上读取荧光值。使用GraphPad Prism 软件从复制曲线中计算IC50 值。
细胞实验 细胞系 MM.1S, MM.1R, RPMI8226, U266, RPMI8266, RPMI-Dox40, OPM1 细胞,原代 MM细胞和 PBMNCs
浓度 溶于DMSO,浓度为 10 mM, 终浓度为 0.25-4 μM
孵育时间 24或48小时
方法 37oC下不同浓度AT7519处理细胞24或48小时。通过测量MTT染料吸光度而测定细胞活性。通过测定摄入的3H胸腺嘧啶(3H-TdR)而测定DNA合成。使用Annexin V/PI染色测评凋亡。细胞是凋亡百分数是早期凋亡数(Annexin V-阳性细胞 )和晚期凋亡数 (Annexin V-阳性和PI-阳性细胞)总和。
实验图片 检测方法 检测指标 实验图片 PMID
Growth inhibition assay Cell viability 20101221
Western blot CDK1 / CDK2 / CDK4 / Cyclin B1 / Cyclin E / CDK9 / CDK5 / CDK6 / Cyclin D1 / Cyclin A 20101221
体内研究(In Vivo)
体内研究活性 AT7519 按9.1 mg/kg剂量作用于 HCT116 和HT29 结肠癌移植瘤模型,每天两次,引起早期和晚期肿瘤衰退。[1] AT7519按 15 mg/kg 剂量作用于携带人类MM移植瘤的小鼠模型,抑制肿瘤生长,这和提高的caspase 3激活相关。[2]
动物实验 Animal Models 皮下注射MM.1S细胞的雄性SCID小鼠
Dosages 15 mg/kg/day
Administration 腹腔注射
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01183949 Completed
Multiple Myeloma
Astex Pharmaceuticals Inc.|Multiple Myeloma Research Consortium
November 2010 Phase 1|Phase 2

化学信息&溶解度

分子量 382.24 分子式

C16H17Cl2N5O2

CAS号 844442-38-2 SDF Download AT7519 SDF
Smiles C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 25 mg/mL ( 65.4 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy AT7519 | AT7519 supplier | purchase AT7519 | AT7519 cost | AT7519 manufacturer | order AT7519 | AT7519 distributor
在线咨询
联系我们